Aortic Stenosis Global Market Report 2025

The aortic stenosis market size has grown rapidly in recent years. It will grow from $7.88 billion in 2024 to $8.93 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth during the historic period can be attributed to an aging population, a rising prevalence of risk factors, advancements in diagnostic technologies, increased awareness of heart diseases, and improvements in healthcare infrastructure.

The aortic stenosis market size is expected to see rapid growth in the next few years. It will grow to $14.54 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The projected growth in the forecast period is driven by the rising adoption of minimally invasive procedures, an expanding geriatric population, increasing healthcare expenditure, improved healthcare access in emerging markets, and advancements in aortic valve replacement technologies. Key trends include robotic-assisted surgery, 3D imaging and visualization, innovations in transcatheter aortic valve replacement (TAVR), the integration of artificial intelligence in diagnostics, and the development of biodegradable stents.

The rising prevalence of heart diseases is expected to drive the growth of the aortic stenosis market. Heart diseases encompass various conditions that affect the heart’s structure and function, potentially impairing its ability to pump blood effectively and leading to severe complications. Common heart diseases include coronary artery disease (CAD), heart failure, arrhythmias, valvular heart disease, and cardiomyopathy. Aortic stenosis, a condition characterized by the narrowing of the aortic valve, obstructs blood flow from the left ventricle to the aorta, increasing resistance and forcing the heart to work harder, which can lead to heart failure and other cardiovascular issues over time. Treatment options such as valve replacement or transcatheter aortic valve implantation (TAVI) help restore proper heart function and reduce the risk of severe outcomes. For example, in January 2025, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK are living with heart and circulatory diseases, including around 4 million males and 3.6 million females. These conditions account for nearly 27% of all deaths in the UK, leading to over 170,000 fatalities annually, or approximately 480 deaths per day. This increasing burden of heart diseases is driving the expansion of the aortic stenosis market.

Leading companies in the aortic stenosis market are focusing on advancements in aortic valve technologies, such as transcatheter aortic valve implantation (TAVI) systems, to improve patient outcomes, reduce procedural risks, and enhance overall treatment effectiveness. The TAVI system is a minimally invasive medical device designed to replace a diseased aortic valve without the need for open-heart surgery. For example, in January 2023, Abbott Laboratories, a US-based medical device company, received approval from the U.S. Food and Drug Administration (FDA) for Navitor, its latest-generation TAVI system. Navitor features the NaviSeal fabric cuff, designed to minimize or eliminate paravalvular leaks. Its leaflet design within the native valve aims to improve coronary artery access for potential future treatments of coronary artery disease, offering enhanced long-term care for patients with aortic stenosis.

In August 2024, Edwards Lifesciences, a US-based heart valve technologies company, expanded its structural heart portfolio through the acquisition of JC Medical for an undisclosed amount. This acquisition strengthens Edwards Lifesciences' capabilities in transcatheter aortic valve replacement (TAVR) technologies by incorporating the J-Valve system, a specialized solution for treating severe aortic regurgitation. JC Medical, a US-based medical device company, is known for developing advanced TAVI systems to address both aortic stenosis (AS) and aortic regurgitation (AR), further enhancing treatment options for patients with complex valvular conditions.

Major players in the aortic stenosis market are AstraZeneca plc, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences Corporation, Biotronik SE & Co. KG, LivaNova PLC, Meril Life Sciences Pvt Ltd., Shockwave Medical Inc., Venus Medtech, Egnite Inc., JenaValve Technology Inc, Peijia Medical, Micro Interventional Devices Inc, CryoLife Inc., Coroneo Meril Life Sciences Pvt Ltd, Thubrikar Aortic Valve Inc., Anteris Technologies Ltd., Cardiawave.

North America was the largest region in the aortic stenosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in aortic stenosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the aortic stenosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Aortic stenosis is a condition in which the aortic valve of the heart becomes narrowed, restricting blood flow from the left ventricle to the aorta and the rest of the body. It is commonly caused by age-related valve calcification, congenital valve defects, or rheumatic fever. Aortic stenosis can result in serious complications such as heart failure, which may be managed with medication or treated through surgical interventions such as valve replacement.

The primary types of aortic stenosis include congenital aortic stenosis and acquired aortic stenosis. Congenital aortic stenosis refers to a narrowing of the aortic valve present at birth, which limits blood flow from the heart's left ventricle to the aorta. Treatment options include surgical aortic valve replacement, transcatheter aortic valve replacement, and balloon aortic valvuloplasty. These treatments are administered through different methods such as oral, parenteral, and implants. Distribution channels are divided into offline and online platforms, while end users include hospital pharmacies, retail pharmacies, and online pharmacies.

The aortic stenosis market research report is one of a series of new reports that provides aortic stenosis market statistics, including aortic stenosis industry global market size, regional shares, competitors with an aortic stenosis market share, detailed aortic stenosis market segments, market trends and opportunities, and any further data you may need to thrive in the aortic stenosis industry. This aortic stenosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aortic stenosis market consists of revenues earned by entities by providing services such as surgical treatments, transcatheter aortic valve replacement, balloon valvuloplasty and medical management. The market value includes the value of related goods sold by the service provider or included within the service offering. The aortic stenosis market includes sales of medical devices, diagnostic and monitoring tools and surgical instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.